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Background/objectives: Nuclear peroxisome proliferator activated receptor-a (PPAR-a) plays a fundamental role in the regulation of lipid
homeostasis and is the target of medications used to treat dyslipidemia. However, little is known about the role of PPAR-a in mouse behavior.
Methods: To investigate the function of Ppar-a in cognitive functions, a behavioral phenotype analysis of mice with a targeted genetic disruption
of Ppar-a was performed in combination with neuroanatomical, biochemical and pharmacological manipulations. The therapeutic exploitability of
PPAR-a was probed in mice using a pharmacological model of psychosis and a genetic model (BTBR T þ tf/J) exhibiting a high rate of repetitive
behavior.
Results: An unexpected role for brain Ppar-a in the regulation of cognitive behavior in mice was revealed. Speciﬁcally, we observed that Ppar-a
genetic perturbation promotes rewiring of cortical and hippocampal regions and a behavioral phenotype of cognitive inﬂexibility, perseveration
and blunted responses to psychomimetic drugs. Furthermore, we demonstrate that the antipsychotic and autism spectrum disorder (ASD)
medication risperidone ameliorates the behavioral proﬁle of Ppar-a deﬁcient mice. Importantly, we reveal that pharmacological PPAR-a agonist
treatment in mice improves behavior in a pharmacological model of ketamine-induced behavioral dysinhibition and repetitive behavior in BTBR
T þ tf/J mice.
Conclusion: Our data indicate that Ppar-a is required for normal cognitive function and that pharmacological stimulation of PPAR-a improves
cognitive function in pharmacological and genetic models of impaired cognitive function in mice. These results thereby reveal an unforeseen
therapeutic application for a class of drugs currently in human use.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Dyslipidemia, a dysregulation of lipid content in the blood, is a leading
risk factor for cardiovascular disease (CVD). Dyslipidemia is treated
with ﬁbrates, which act as agonists of the nuclear receptor peroxisome
proliferator-activated receptor-a (PPAR-a) [1,2]. This protein is one of
three PPAR isotypes, PPAR-a, PPAR-g, and PPAR-d, which display
distinct physiological functions dependent on their differential ligand
activation proﬁles and tissue distribution [3,4]. PPAR-a is abundantly
expressed in skeletal muscles and liver where it increases lipoprotein
lipase activity, increases production of enzymes associated with b-
oxidation and augments levels of both ApoA-I and high density lipo-
protein cholesterol (HDL-C) [5,6].
PPAR-a is also expressed in the brain, where its effects have not
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some antipsychotic and autism spectrum disorder (ASD) medications.
Speciﬁcally, Ppar-a activation improves antipsychotic medication
adverse event oral tardive dyskinesia [7] and indirectly reduces the
activity of dopamine cells in the ventral tegmental area in rodents [8].
In humans, dyslipidemia is more prevalent in individuals with
schizophrenia and ASD compared to the general population [9,10],
with one of the leading causes of premature death in these patients
being CVD [1]. Several genetic association studies report an asso-
ciation between apolipoprotein E (ApoE), which plays an important
role in lipoprotein metabolism and CVD, and schizophrenia [11].
Though individuals with schizophrenia and ASD may be at greater
risk of dyslipidemia and subsequent CVD, the link between these
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Here we considered whether the cellular machinery that evolved to
modulate energy availability also plays a neurodevelopmental role
inﬂuencing cognitive behavior.
2. MATERIALS AND METHODS
2.1. Animals
For all experiments, male mice aged 3e5 months were used. No
genotypic differences in body weight were evident at the time of
testing. All procedures met the European guidelines for the care and
use of laboratory animals (86/609/ECC and 2010/63/UE) and those of
the Italian Ministry of Health (D.L. 116/92). Male wild-type and Ppar-a
/ (B6.129S4-SvJae-Pparatm1Gonz) mice previously backcrossed
to C57BL6 mice for 10 generations were bred in house, and the colony
was established and maintained by heterozygous crossing. Mice were
genotyped as described on the supplier webpage (http://jaxmice.jax.
org), with minor modiﬁcations. DNA was extracted from tails using
the RedExtract kit (SigmaeAldrich, Italy).
BTBR Tþ Itpr3tf/J mice were purchased from Jackson Laboratory and a
colony was maintained. All animals were housed in a 12-h light/12-h dark
cycle with free access to water and standard laboratory chow diet. For all
peripheral treatments, a volume of 10 ml/kg of solution was used.
2.2. Stereotaxic surgery
C57BL6 mice were injected with buprenorphine (0.05 mg/kg1, SC)
30 min before surgery and then anesthetized using a mixture of ketamine
and xylazine (100 þ 10 mg/kg1, IP). Mice were prepared for surgery,
placed in a stereotaxic apparatus (Kopf Instruments) and a small incision
was made in the skin above the skull. A drop of a pharmaceutical H2O2
solution was placed on the skull to increase visualization of bregma and
lambda. A small holewas carefully drilled into the skull and a guide cannula
(2.0 mm, 26G, Plastics One) aimed at the lateral ventricle (þ1.0 mm
(lateral), 0.6 mm (posterior) from bregma) was implanted using atlas
coordinates (Paxinos and Franklin, 2001) and secured using dental
cement. For ICV treatment, 3 ml of vehicle or drug was injected into the
lateral ventricle over 1min, using a 5e10ml Hamilton syringe connected to
a calibrated polyethylene tube. Cannula placement was conﬁrmed at the
end of the experiment through injection of methylene blue.
2.3. Behavioral assays
2.3.1. Novel Object Recognition (NOR) test
The NOR assay consisted of three testing sessions: a training session
followed by two retention trials 15 min and 24 h later. Mice were
habituated to the testing arena for two consecutive days before the test.
During the training session, two different objects (A and B) were placed in
the testing arena. Each animal was allowed to explore the objects for
5 min. The mouse was considered to be exploring the object when the
head of the animal was facing the object or the animal was touching or
snifﬁng the object. The total time spent exploring each object was
recorded by a trained observer blind to treatment condition and
expressed as percentage of total exploration time. In the retention ses-
sions, one identical and one novel object (A and C or D) were used. A
mouse was allowed to explore the objects for 5 min, and the time spent
exploring each object was recorded. Exploration time was normalized as
percentage of total exploration time. Preference for the novel object was
considered as successful retention of memory for the familiar object.
2.3.2. Marbles burying test
20 small marbles were arranged in 5  4 rows in clean Plexiglas
cages with fresh bedding (5 cm deep). Mice were introducedMOLECULAR METABOLISM 4 (2015) 528e536  2015 The Authors. Published by Elsevier GmbH. This is a
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tions. After 15 or 30 min, the mouse was removed and the number of
unburied marbles was counted. A threshold of 75% coverage was
used to determine whether the marbles were buried.
2.3.3. Self-grooming
Mice were manually scored for self-grooming behavior over a period of
10 min under dim light and white-noise conditions.
2.3.4. Spatial learning and memory tests
The Morris Water Maze (MWM) is a circular pool (diameter 170 cm,
height 60 cm). The water temperature, 23  1 C, light intensity,
external cues in the room, and water opacity were rigorously
reproduced. A transparent Plexiglas non-slippery platform (diameter
10 cm) was immersed under the water surface (about 1.5 cm) during
acquisition trails. Swimming was recorded using a camera coupled
with video tracking software (Any-maze, Stoelting). Training consisted
of 4 swims per day for 9 days, with a 15 min inter-trial interval. Start
positions were pseudo-randomly selected and each animal was
allowed a 60 s swim to ﬁnd the platform. Once the mouse reached
the platform it was allowed to remain on the platform for 15 s. The
latency, expressed as mean  SEM, was calculated for each training
day. A probe test (60 s) was performed 24, 48 and 72 h after the last
swim on day 9. The platform was removed, and each animal was
allowed a free 60 s swim. The start position for each mouse cor-
responded to one of two positions remote from the platform location
in counterbalanced order. The platform quadrant was termed the
target quadrant and the percentage of time spent in the target
quadrant was determined.
2.3.5. Reversal learning
A different cohort of mice was trained in the MWM apparatus as
described above. On day 10, the platform was moved into a different
MWM quadrant (see Figure 2G). The distance swum and the latency to
ﬁnd the new platform position together with the number of crossing on
the previous platform position were recorded.
2.3.6. Spontaneous alternation performance
Each mouse, naïve to the apparatus, was placed at the end of one arm
in a Y-maze (three arms, 40 cm long, 120  separate) and allowed to
move freely through the maze during a single 5 min session. The series
of arm entries, including possible returns into the same arm, was
recorded visually. An alternation was deﬁned as entries into all three
arms on consecutive trials. The number of the total possible alterna-
tions was therefore the total number of arm entries minus two, and the
percentage of alternation was calculated as correct alternations/
possible alternations  100.
2.3.7. NMDA antagonist-induced locomotion
Mice were allowed to explore the arena for 30 min, and their activity
was monitored using a video tracking software (Any-maze, Stoelting).
After 30 min, recording was paused, mice were injected with vehicle
or treatment and immediately returned to the arena, and the video
recording re-initiated. MK-801 was administered at a dose of 0.1 mg/
kg1; SC and its effect recorded for 120 min. Ketamine was
administered at a dose of 20 mg/kg1; IP and its effect recorded for
60 min.
2.4. EEG recordings
Ppar-a/ and wild type littermates were chronically implanted with
ﬁve electrodes under tiletamine/zolazepam (1:1; Zoletil 100; 50 mg/n open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 529
Figure 1: Ppar-a L/L mice display enhanced behavioral perseveration and repetition.
(A) Ppar-a / mice display enhanced perseveration for the familiar object in the novel object recognition task (n ¼ 8/genotype; **p < 0.01, two-tailed Student’s t-test). Ppar-
a / mice display enhanced repetitive behavior in the (B) marble burying test and (C) self-grooming test (3-4 months-old male mice n ¼ 8e9/genotype; **p < 0.01 vs WT, two-
tailed Student’s t-test). (D) appearance of facial hair loss in young-adult Ppar-a / mice. (E) skin lesions in middle-aged Ppar-a / mice.
Original articlekg, IP; VIRBAC Srl, Milan, Italy) anesthesia. Electrode leads were sol-
dered to a miniature connector, which was head-mounted with cra-
nioplastic cement and mounting screws. Mice were allowed 1 week of
recovery and handled twice a day. Mice were attached to a multi-
channel ampliﬁer (Stellate Harmonie Electroencephalograph; Montreal,
Quebec, Canada) by a ﬂexible recording cable and an electric swivel,
ﬁxed above the cages, permitting free movements. Mice were accli-
mated to the recording conditions for 3 days before the experiments.
EEG recordings were performed starting at 9:00 a.m. Signals were
ampliﬁed and conditioned by analog ﬁlters (ﬁltering: below 0.5 Hz and
above 70 Hz) and subjected to an analog-to-digital conversion with a
sampling rate of 300 Hz. Quantitative EEG analysis was performed
using the Fast Fourier Transform (FFT) and a commercial software
(Stellate Harmonie Electroencephalograph; Montreal, Quebec, Can-
ada). The bipolar signal from each cortical area in both brain hemi-
spheres was processed using FFT and the main spectral components
separated. Five main band components were identiﬁed in the fre-
quency range between 0.5 and 70 Hz: delta (0.5e3.9 Hz), theta (4.0e
7.9 Hz), alpha (8.0e12.9 Hz) and beta (13.0e30 Hz) and gamma (30e
70). In both wild type and Ppar-a / mice, the mean power (in mV2)
of each of these components was computed by integration of the
power spectra in the respective frequency ranges.530 MOLECULAR METABOLISM 4 (2015) 528e536  2015 The Authors. Published by Elsevier2.5. Biochemical and histological assays
2.5.1. Preparation of tissue protein extracts and western blot
analysis
Dissected brain samples were homogenized on ice-cold lysis buffer
(10 mM TriseHCl, 20 mMpH 7.5, 10 mMNaF, 150 mMNaCl, 1%
Nonidet P-40, 1 mM phenylmethylsulphonyl ﬂuoride, 1 mM
Na3VO4, leupeptin and trypsin inhibitor 10 mg/ml; 0.25 ml/50 mg
tissue). After 1 h, tissue lysates were centrifuged at 14,000 rpm for
15 min at 4 C. Protein lysates (30e50 mg) were separated on a
10% SDS-polyacrylamide gels. Membranes were probed with pri-
mary (mouse anti-Parvalbumin, MAB1572, Millipore, 1:500; rabbit
anti-PPAR-alpha, P0369, SigmaeAldrich, 1:500; mouse anti-b-
actin, A5441, SigmaeAldrich, 1:5000) and the appropriate sec-
ondary antibodies (Jackson ImmunoResearch, PA, USA). Immuno-
reactive bands were visualized by chemiluminescence using the
ImageQuant400 system (GE Healthcare) and the Quantity One
Software 4.6.3 (Biorad).
2.5.2. Brain sectioning and immunoﬂuorescence
Mice were deeply anesthetized with pentobarbitone (50 mg/kg1, IP)
and transcardially perfused with phosphate buffered saline (PBS)GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: Ppar-aL/L mice exhibit impaired behavioral ﬂexibility. Ppar-a / mice display unaffected spatial memory in the Morris Water Maze (MWM) test. (A) Escape
latency, (B) average speed, and (C) percentage of time spent in the target quadrant across 9 days of MWM reference platform task shows that Ppar-a / mice performed
similarly to wild-type controls on the spatial hidden platform task. (D) Schematic of the MWM (“>” indicates entry points). (E) Occupancy plots during repeated MWM probe tests.
(F) Time spent in the target quadrant during probe tests; although Ppar-a / mice and wild-type controls spent a signiﬁcant percentage of time in the target quadrant (p < 0.05
vs a change level of 15 s; Wilcoxon signed-rank test), during the 72-hours probe test a signiﬁcant genotype-dependent difference was observed (*p < 0.05, two-tailed Student’s t-
test). Ppar-a / mice have impaired behavioral ﬂexibility. (G) Schematic of the reversal setting of the MWM test. (H) Latency to locate the new platform position (tick on the x-
axis represent test trials; two-way repeated measures ANOVA: effect of genotype; F(1,14) ¼ 30.93, p < 0.0001; effect of time: F(11,154) ¼ 34.24, p < 0.0001; interaction
F(11,154) ¼ 5.18. p < 0.0001; followed by Bonferroni post hoc test **p < 0.01 vs wild type mice at given trials; n ¼ 8). (I) Higher number of previous platform position crossings
during reversal phase of task compared to controls (*p < 0.05 vs WT, two-tailed Student’s t-test; n ¼ 8). (J) Right, Y-maze spontaneous alternation performances and, left, total
numbers of arm maze entries (3-5 months-old male mice n ¼ 10e12; *p < 0.05 vs WT, two-tailed Student’s t-test).followed by 4% paraformaldehyde (PFA). Following extraction, brains
were post ﬁxed overnight in 4% PFA and then transferred to 20%
sucrose for cryoprotection. Brains were sectioned on a cryostat at
25 mm and collected in ﬁve equal series of adjacent tissue. Free-
ﬂoating sections were washed in PBS, incubated in blocking buffer
(0.5% BSA, 0.5% Triton-X 100 in PBS) for 60 min and then incubated
overnight in blocking buffer containing primary antibodies (mouse anti-
Parvalbumin, MAB1572, Millipore, 1:1000). Sections were then
washed in PBS and incubated for 60 min with secondary antibody
(Donkey Anti-Mouse IgG, Alexa Fluor 488, Abcam, 1:500). Sections
were rinsed in PBS, mounted onto glass microscope slides and cover-
slipped in an aqueous mounting medium (Vectastain, Vector
Laboratories).
2.6. Chemicals
All chemicals were from Tocris (Avonmouth, UK), unless otherwise
indicated. Fresh drug solutions were prepared immediately before use.MOLECULAR METABOLISM 4 (2015) 528e536  2015 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.comGW7647 was administered IP in a vehicle of 0.9% sterile saline with
5% polyethylene glycol (PEG)-400 and 5% Tween 80. WY-14643 was
administered in a vehicle of distilled water/5% polyethylene glycol
(PEG) 400 and sonicated before injection.
2.7. Statistics
Data are expressed as mean  SEM. Two experimental group com-
parisons were made using the Student’s t-test. When more than two
experimental groups were present, data were analyzed using one-way
ANOVA followed by the Dunnett’s post hoc multiple comparison test.
Water-maze escape latencies were analyzed over trials using repeated
measures ANOVA. For the probe test of MWM, the time spent in the
training quadrant was analyzed vs. the chance level (15 s), and for
novel object recognition preference for the new object during the
retention trail was analyzed vs. the chance level of 50% using Wilcoxon
Signed Rank Test. The level of statistical signiﬁcance was set at
p < 0.05.n open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 531
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3.1. Ppar-a loss of function promotes repetitive behavior and
cognitive inﬂexibility
To investigate the role of Ppar-a in behavior, we characterized wild
type and Ppar-a deﬁcient mice in ﬁve behavioral assays: novel object,
marble burying, home cage self-grooming, Morris Water Maze (MWM)
and Y maze.
Mice were ﬁrst tested for short-term memory through the presentation
of a novel object 10 min after the sampling phase (Figure 1A). During
the sampling phase of the object recognition test, both wild type and
Ppar-a / mice interacted equally with the two objects. During the
short-term test, wild type mice showed a preference for the novel
object, whereas Ppar-a / mice clearly preferred the familiar object
(Figure 1A). This observation suggests a conservative behavior of mice
lacking Ppar-a, and we interpreted the preference for the familiar
object during the object recognition task as indicative of a repetitive/
perseverative behavioral trait. To further explore this repetitive/
perseverative phenotype, mice were assessed in a marble burying test,
wherein mice are scored for the number of marbles they bury from the
top of the bedding as an index for repetitive/perseverative behavior and
compulsion [12]. We observed that Ppar-a / mice buried signiﬁ-
cantly more marbles than wild type littermates (Figure 1B), indicative of
greater repetitive/perseverative behavior.Figure 3: Ppar-a loss of function promotes an NMDA hypofunction-like condition. N
mice. (A) Time course of MK-801einduced locomotor activity (0.1 mg kg-1 subcutaneous
Time course of ketamineeinduced locomotor activity (20 mg/kg1, IP; two way ANOVA r
expression of parvalbumin (PV) interneurons in Ppar-a null mice; immunoﬂuorescence (P
pocampus (middle panel; scale bar 200 mm). Bottom panel e digital magniﬁcation of co
cortical and hippocampal explants. (E) Alterations of baseline cortical oscillations in awake
and theta (bottom) frequency bands are shown (n ¼ 6 mice/genotype; **p ¼ 0.0022, tw
532 MOLECULAR METABOLISM 4 (2015) 528e536  2015 The Authors. Published by ElsevierThe novel object and marble burying assays investigate the response
of mice to unfamiliar objects; however, we also considered whether
repetitive behavior was also evident in the home cage environment. We
scored mice on home cage behavior and observed that Ppar-a /
mice exhibited a signiﬁcant increase in self-grooming behavior
(Figure 1C). Furthermore, by 3 months of age, Ppar-a / mice
developed facial hair loss and sporadic skin lesions (Figure 1D), and
the severity of this phenotype increased with age (Figure 1E). This
phenomenon did not occur in wild type littermates, even when co-
housed with Ppar-a / mice, and is consistent with behavioral
repetition and grooming endophenotypes observed in other genetic
mouse models [13e15]. Collectively, these data provide converging
evidence of increased repetitive and perseverative behavior as a
consequence Ppar-a loss of function.
To conﬁrm that these behavioral effects are not related to global
memory impairment, we investigated the impact of genetic Ppar-a
deﬁciency on spatial reference memory using the Morris Water Maze
(MWM) task (Figure 2AeF). Ppar-a / mice exhibited a modestly
less efﬁcient strategy for locating the hidden platform, with a some-
what shorter escape latency (Figure 2A) and faster swimming speed
(Figure 2B). However, the percentage of time spent in the target
quadrant increased over test sessions in a manner indistinguishable
from wild type littermates (Figure 2C), indicating unaffected learning
overall. Furthermore, there was no genotypic difference in memoryon-competitive NMDAR antagonisteinduced locomotion is diminished in Ppar-a /
; two way ANOVA repeated-measures; F(1,360) ¼ 5.81, p ¼ 0.0292; n ¼ 7e11). (B)
epeated-measures; F(1,348) ¼ 6.29, p ¼ 0.0275; n ¼ 7e9). (C) Decreased cortical
V) staining in the prefrontal infralimbic cortex (top panel; scale bar 200 mm) and hip-
rtical PV interneurons (scale bar 50 mm). (D) Western blot of PV expression in frontal
behaving Ppar-a / mice. Average relative power in the alpha, beta (top) and gamma
o-tailed Mann Whitney test).
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Figure 4: Risperidone improves repetitive behavior in Ppar-a null mice. Effect of
7e10 days treatment with risperidone (0.01 mg/kg1, IP) on marble burying behavior
(A) and self-grooming (C). Re-appearance of the increased marble burying (B) and
self-grooming behaviors (D) one week after treatment’s suspension (3 months-old
male mice n ¼ 8e12; *p < 0.05 and **p < 0.01 vs wild type mice, &p < 0.05 vs
Ppar-a / mice treated with vehicle; one-way ANOVA, followed by Tukey’s multiple
comparisons test).retention during the MWM test one day after the last learning session
(Figure 2E, F), suggesting that Ppar-a is not required for spatial
memory retention. Moreover, tests performed 48 and 72 h later
revealed that both wild type and Ppar-a / mice spent more time in
the target quadrant above the chance level of 25%, indicating
appropriate memory retention for the location of the escape platform.
However, while wild type mice began to explore other quadrants of the
maze seeking different escape possibilities, Ppar-a / mice spent
more time in the target quadrant with minimal exploration in other
areas (Figure 2E, F).
We next assessed a new cohort of mice in a reversal-learning task in
the MWM by changing the location of the escape platform after mice
had learned its position (Figure 2D, G). Ppar-a/ mice manifested a
deﬁcit for reversal learning, showing a strong bias toward the platform
location they acquired during the training phase, measured as latency
to located the new platform position (Figure 2H) and the number of old
platform coursing (Figure 2I). These ﬁndings were further supported in
another behavioral assay, the Y-maze. Again, despite no alterations in
reference spatial memory, Ppar-a / mice displayed a signiﬁcant
impairment in spontaneous alternation when tested in the Y-maze
(Figure 2J).
Together, these data suggest that Ppar-a is not required for the
acquisition of spatial learning and memory. However, Ppar-a is
required for spatial information processing and cognitive ﬂexibility and
loss of functional Ppar-a leads to a repetitive/perseverative behavioral
phenotype.
3.2. Ppar-a loss of function promotes an NMDA hypofunction-like
condition
We next investigated the response of Ppar-a / mice to a phar-
macological model of NMDA hypofunction. Mice were challenged with
vehicle or NMDA receptor antagonists that promote behavioral dysin-
hibition, MK-801 (0.1 mg kg1, SC) or ketamine (20 mg kg1, IP) [16].
Ppar-a / mice were hypo-responsive to the locomotor effects of
both MK-801 (Figure 3A) and ketamine (Figure 3B) in the open ﬁeld
assay. Thus, these results reveal that mice lacking Ppar-a are resistant
to the behavioral dysinhibitory effect of NMDA antagonists.
We next examined the neural substrates underpinning Ppar-a /
mouse resistance to NMDA antagonists. One possibility is that Ppar-a
loss of function promotes morphological remodeling of the cortex and/
or hippocampus. To investigate this, we examined the anatomical
organization of the brain of Ppar-a / and wild type littermates. No
gross abnormalities in brain structure were evident (data not shown).
NMDA receptor antagonists induce cortical excitation through a
reduction in NMDA receptor function that preferentially decreases the
ﬁring rate of fast-spiking parvalbumin positive (PVþ) GABA-ergic in-
terneurons [17,18], resulting in dysinhibition of pyramidal neurons. The
net effect is cortical excitation [19,20]. Using both immunoﬂuores-
cence staining and western blotting techniques, we investigated the
expression proﬁle of parvalbumin interneurons in the frontal cortex and
hippocampus. We observed that Ppar-a / mice displayed a
reduction of PV þ interneurons in frontal cortex and hippocampus
(Figure 3C, D), and that remaining PV þ interneurons appeared
dystrophic (Figure 3C, bottom panel). These data provide an
anatomical explanation for the hypo-responsiveness of Ppar-a /
mice to NMDA antagonists.
To further examine whether this anatomical impairment impacts brain
function, we performed EEG. PV þ interneurons are essential for
synchronization of neural activity, and their impairment causes EEG
alterations [21e23]. EEG recordings in freely moving mice revealed a
genotype-dependent difference between Ppar-a / mice and wildMOLECULAR METABOLISM 4 (2015) 528e536  2015 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.comtype littermates. Deletion of Ppar-a caused an abnormal increase in
gamma waves, while theta frequency was lower compared to wild type
mice (Figure 3E). Together, these data reveal that Ppar-a loss of
function impacts the structural morphology and functional integrity of
the cortex and hippocampus and the synchronization of neural activity.
3.3. Antipsychotic medication improves repetitive behavior in Ppar-
a / mice
To investigate whether the behavioral alterations observed in Ppar-
a / are ameliorated by antipsychotic medication, wild type and
Ppar-a / littermates were treated with risperidone or vehicle for
7e10 days and were then assessed in the marble burying assay, self-
grooming in the home cage and MWM tasks. Risperidone (0.01 mg/kg,
IP) normalized the behavior of Ppar-a / mice in the marble burying
test (Figure 4A), and it reversed the elevated self-grooming behavior
(Figure 4C). It did not, however, correct the reversal-learning deﬁcit in
the MWM (data not shown). Mice were retested 7 days after risperi-
done was withdrawn, and both marble burying and self-groomingn open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 533
Original articlebehavior returned to levels similar to those observed in unmedicated
mice (Figure 4B, D). Thus, Ppar-a / mice exhibit an improved
behavioral proﬁle when treated with an antipsychotic medication.
3.4. Pharmacological activation of PPAR-a reduces NMDAR
antagonisteinduced locomotion and reduces repetitive behavior in
BTBR T þ tf/J mice
To investigate the therapeutic application of our ﬁndings, we next
probed the consequence of pharmacological activation of PPAR-a in
preclinical models of schizophrenia and ASD. We hypothesized that the
activation of brain PPAR-a would be sufﬁcient to attenuate the psy-
chomimetic action of the NMDA receptor antagonist ketamine. Keta-
mine was selected because it induces symptoms associated with
schizophrenia in healthy human volunteers and as such is used as a
pharmacological model of schizophrenia-like behavior. Wild type mice
were pretreated with the selective PPAR-a agonist GW7647 (3 mg, ICV)
and treated with ketamine (20 mg kg1, IP). PPAR-a agonist treatment
reduced ketamine-induced hyperlocomotion in the open ﬁeld assayFigure 5: Pharmacological activation of Ppar-a reduces NMDAR antagonisteinduce
administration of a selective PPAR-a agonist reduces ketamineeinduced locomotion. (A)
brain ventricle (ICV) 30 min before ketamine (20 mg kg-1, IP). (B) The cumulative locomoti
ketamine group; two-tailed Student’s t-test). (C) Down-regulation of cortical PPAR-a follow
agonist ameliorates behavioral repetition in a genetic model of ASD e the BTBR Tþ tf/
treatment for 7e10 days followed by a wash out week. (E) Effect of GW767 treatment on
treated mice, &p < 0.05 vs GW767-treated; one-way ANOVA, followed by Tukey’s multip
534 MOLECULAR METABOLISM 4 (2015) 528e536  2015 The Authors. Published by Elsevier(Figure 5A, B). Further underscoring a link between Ppar-a brain
expression and cortical dysinhibition, we observed that during a period
of sustained cortical dysinhibition, wild type mice displayed lower
levels of cortical PPAR-a when treated with two injections of ketamine
(Figure 5C). Therefore, these data reveal that activation of PPAR-a is
effective in improving the psychomimetic effect of ketamine.
We next assessed the effect of PPAR-a agonist GW7647 on behavior in
BTBR T þ tf/J (BTBR) mice, a mouse model that displays reliable face
validity for ASD [24,25], including high rate of repetitive behavior [26].
BTBR mice were treated with GW7647 (15 mg/kg, IP) or vehicle for 10
days and subsequently scored for spontaneous marble burying and
self-grooming behaviors (Figure 5D). PPAR-a activation signiﬁcantly
reduced the number of buried marbles (Figure 5E) and improved the
spontaneous grooming behavior (Figure 5F) in BTBR mice. Seven days
after GW7647 treatment was withdrawn, behaviors returned to levels
similar to those observed in untreated BTBR mice. These data suggest
that daily treatment with a PPAR-a agonist improves repetitive
behavior in BTBR mice.d locomotion and reduces repetitive behavior in BTBR TD tf/J mice. A single brain
Treatment schematic: the PPAR-a agonist, GW767 (3ug) administered into the lateral
on during the habituation and after ketamine injection (n ¼ 6e7; *p < 0.05 vs vehicle-
ing repeated ketamine injections in wild type mice (n ¼ 3). Treatment with a PPAR-a
J mice (male, 14 weeks of age). (D) Treatment schematic: GW767 (15 mg kg-1, IP)
the marbles burying and (F) self-grooming behavior (n ¼ 8e10; *p < 0.05 vs vehicle
le comparisons test).
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4. DISCUSSION
PPAR-a is best characterized for its contribution to the regulation of lipid
homeostasis and its utility as a target for the treatment of dyslipidemia.
However, little is known about its function within the brain. Here we
reveal an unexpected role for Ppar-a in cognitive behavior in mice.
Speciﬁcally, we report that genetic inactivation of Ppar-a resembles a
behavioral and cognitive phenotype consistent with preclinical models
of schizophrenia and ASD. In an effort to elucidate the mechanism
through which this phenotype is mediated, we analyzed the brain. We
observed that the genetic prevention of Ppar-a activity produced a
reduction in cortical PV þ GABAergic interneurons, consistent with
post-mortem analyses of brains from patients with schizophrenia [27e
30]. We also report that the behavioral proﬁle of Ppar-a null mice was
improved with antipsychotic risperidone treatment. Thus, Ppar-a
deﬁcient mice may represent a new preclinical model to investigate the
etiology and/or treatment of schizophrenia. The behavioral proﬁle of
Ppar-a null mice also shows similarities with ASD mouse model BTBR,
which displayed an improved repetitive behavior with PPAR-a agonist
treatment. Furthermore, risperidone is also used to alleviate hyper-
activity, self-injurious, and repetitive behavior symptoms in humans
suffering with ASD [31,32]. Together, these results highlight PPAR-a
as a potential point of commonality between schizophrenia and ASD
worthy of further investigation.
Considering that repetitive behaviors can arise from a disruption in the
direct cortico-striatal circuit, it is possible that PPAR-a plays an instru-
mental role in the organization and orchestration of PV þ interneuron-
pyramidal neuron cortical microcircuitry, and the absence of this regu-
lation contributes to a net increase in cortical ﬁring and output onto
striatal structures. Supporting this possibility, GABAergic interneurons
are crucial for synchronization of network activity, Ppar-a / mice
exhibit abnormal EEG waves, and Ppar-a/ mice are resistant to the
behavioral dysinhibition caused by the administration of NMDA receptor
antagonists, which inhibit the activity of cortical PV þ interneurons.
Given our observation that PPAR-a agonist treatment improves
behavior in a pharmacological model of psychosis (ketamine) and a
mouse model that displays face validity for ASD (BTBR) [24e26], our
research suggests that patients with schizophrenia and ASD co-
prescribed ﬁbrates to improve dyslipidemia may show a greater
beneﬁt in cognitive symptom amelioration. This possibility warrants
further investigation in patient populations. Moreover, it is possible that
at least a subset of these patients may receive direct therapeutic
beneﬁt from ﬁbrates. If this were the case, it would have the added
beneﬁt of overcoming the metabolic disturbance associated with many
current antipsychotic medications [33e37]. Of interest, loss of function
of Ppar-a results in middle age-onset obesity/weight gain in mice [38].
Thus, increasing the activity of PPAR-a with compounds such as
ﬁbrates in patients may serve a further metabolic-protective role.
In conclusion, our ﬁndings disclose a previously unknown role for Ppar-
a in cognitive function in mice. In addition to highlighting a neurological
phenotype resulting from the loss of function of Ppar-a, our ﬁndings
also suggest that this receptor may represent a target for the phar-
macological amelioration of neurological conditions associated with
behavioral perseveration/repetition. This is a particularly attractive
prospect given that naturally occurring and synthetic PPAR-a agonists
are currently used in clinical practice.
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